Ann: INV103 ala-Cpn10 clinical trial in lupus complete, page-3

  1. 48 Posts.
    Finally we have one lot of results released!!!
    Fantastic to see the safety is still there even with a dosing increase of 10 fold compared to what had been done previously.
    I'm not getting to bogged down in the biomarkers as the primary goal of this study was to increase the dosage to see if it is still safe, keep in mind there was only 28 patients so too small to factor in biological changes. Now we can have the larger and longer study into Cpn10 for autoimmune diseases. Lets see who we can partner up with and drive this science further!!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.6¢
Change
0.000(0.00%)
Mkt cap ! $8.199M
Open High Low Value Volume
9.6¢ 9.8¢ 9.6¢ $3.656K 38.07K

Buyers (Bids)

No. Vol. Price($)
2 20756 9.6¢
 

Sellers (Offers)

Price($) Vol. No.
9.9¢ 146502 2
View Market Depth
Last trade - 15.11pm 07/08/2025 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.